• Calvin Summer, MD, was named chief medical officer and senior VP of clinical development for BioBehavioral Diagnostics (Cambridge, Massachusetts). Most recently, Sumner held senior clinical development positions at Eli Lilly in the U.S. medical division of Lilly research laboratories. BioBehaviorial Dignostics makes diagnostic systems for psychiatric and behavioral disorders.

• Patrick Jeanmart was named CFO of Cardio³ BioSciences (Braine L’alleud, Belgium). Most recently, Jeanmart was VP of finance for IBA Molecular. Cardio³ BioSciences is a biotechnology company focused on regenerating heart muscle via cardiac lineage-committed stem cell therapy for patients with congestive heart failure.

• Edward Hammel was promoted to COO of Ivivi Technologies (Northvale, New Jersey). Hammel previously was Ivivi’s executive VP. Ivivi Technologies makes non-invasive electrotherapeutic technologies.

• Graham Powis was named managing director of Lazard’s (New York) U.S. equity capital markets business. Powis was previously managing director and head of equity capital markets at Cowen & Co. Lazard is a financial advisory and asset management firm.

• MEDecision (Wayne, Pennsylvania), a provider of collaborative care management software, and its partner, Medem (San Francisco), a provider of online physician-patient communications services said that Henry DePhillips, MD, executive VP and chief medical officer at MEDecision, is joining Medem. MEDecision founder and CEO David St. Clair said, “Henry joined MEDecision as its first chief medical officer and has been a valuable catalyst. Now, we’re crossing a threshold, moving from a company launching initiatives to a company building on those initiatives. We will continue to focus on leveraging the programs that we worked closely with Henry to launch and look forward to collaborating with him on several of those programs at Medem.”